Cellular Dynamics International, Inc. (CDI), the world’s largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell™ Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells).
“CDI’s mission is to be the top developer and manufacturer of standardized human cells in high quantity, quality and purity and to make these cells widely available to the research community. Our MyCell Services provide researchers with unprecedented access to the full diversity
International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
Osteoarthritis is a very common joint disorder. Due to age and normal wear and tear on the joints, the cartilage that protects the joint begins to break down, causing the bone to rub together which leads to pain and swelling in the joints. There is no cure for osteoarthritis, and up until now, many patients feel that surgery is their only option to manage the symptoms.
However, recently orthopaedic investigators have been studying the effects of periodic injections to the knee of stem cells from synovium, a thin membrane covering the inside of the joint. Nobutake Ozeki from Tokyo Medical
Stem Cell Research Provides Help for Breast Reconstruction
Irene MacKenzie had a lumpectomy for her early stage breast cancer leaving her with a hollow in her breast. The lumpectomy took care of the cancer, but what about her breast? Well, Irene was the first person in Britain to reap the benefits of Stem Cell […]
The very first human trials of a treatment using induced pluripotent stem cells (iPS cells) in Japan will begin as early as next year, the government-backed Riken research institute announced on June 12.
Speaking at a meeting of the Japanese Society for Regenerative Medicine in Yokohama, research team leader Masayo Takahashi of the Riken Center for Developmental Biology detailed plans to begin using iPS treatments on patients with a degenerative eye condition. Transplanted iPS cells have not developed into cancer in animal testing, and the clinical trial will go ahead now that it’s confirmed that similar procedures do not pose